Skip to content

The application of isolation surgery in treating aggressive fibromatosis and low-grade liposarcoma involving neurovascular structures:a prospective single arm study

The application of isolation surgery in treating aggressive fibromatosis and low-grade liposarcoma involving neurovascular structures:a prospective single arm study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079763
Enrollment
Unknown
Registered
2024-01-11
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggressive fibromatosis, low-grade liposarcoma

Interventions

Isolation surgery:Isolation surgery

Sponsors

The First Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? pathologically diagnosed aggressive fibromatosis and low-grade liposarcoma; ? aged 6-70 years; ? tumor located at extremities and involving adjacent major vessels and/or nerves, and R0 resection margin cannot be achieved while preserving involved vessels and/or nerves; ? progressive aggressive fibromatosis during active surveillance or adjuvant therapy. ? Consideration of medical history, clinical, laboratory and imaging examinations, scores, etc., to determine whether surgical treatment can be tolerated; ? Agree to join this study and sign the consent form. The compliance is good and consistent.

Exclusion criteria

Exclusion criteria: ? Patients with serious heart, liver and kidney diseases, pregnant or lactating patients; ? Uncorrectable bleeding tendency or coagulation dysfunction; ? Presence of systemic infection or puncture site infection; ? According to the judgment of the researcher, the patient may have other factors that may lead to the forced midway termination of this study, such as other serious diseases or serious laboratory abnormalities, or other factors that will affect the safety of the subject, unable to tolerate surgical treatment, or the family or society of the test data and sample collection;

Design outcomes

Primary

MeasureTime frame
3-year event-free survival;

Secondary

MeasureTime frame
Adverse effect occurrence rate ;

Countries

China

Contacts

Public ContactJunqiang Yin

The First Affiliated Hospital of Sun Yat-Sen University

yinjunq@mail.sysu.edu.cn+86 20 8775 5766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026